The Efficiency Revolution at Protein Research Companies

With surging industry demand and technical barriers still in place, how can protein research companies become 'game-changers'? If you've ever worked in protein-related research or development, you're probably all too familiar with the following scenarios.

Want a highly active, high-purity recombinant protein? You often have to repeatedly screen expression systems, optimize purification processes, and carry out activity validation, taking months without guaranteed results.

Want to modify an enzyme's activity? Then you're basically looking for a needle in tens of thousands of mutants.

Want to design a brand-new binding protein? You're limited by the accuracy of structure prediction and the bottleneck in experimental verification throughput.

These are the long-standing core pain points in the field of protein research: huge demand, but R&D efficiency always lags behind imagination.

1. A Raging Market and Breathing R&D

Let's first look at some data:

According to Frost & Sullivan, the market size of China's biological research reagents grew from 8.2 billion yuan in 2016 to 15.1 billion yuan in 2020, with a compound annual growth rate of 16.51%, and is expected to reach 34.6 billion yuan by 2025. Among these, protein-based biological reagents are a key part of the market, accounting for about 30% to 35%. Behind this growth is the continuous expansion of investment in biopharmaceutical research and development and the ever-broadening downstream application scenarios.

Focusing more on the field of protein purification services, according to Hengzhou Chengsi, the global market size for recombinant protein purification services in 2024 is about 21.5 billion yuan, expected to approach 32.46 billion yuan by 2031, with a compound annual growth rate of about 6.0%. Regarding the global recombinant protein production service market, it will reach around 13.7 billion yuan in 2024 (converted at a 1:7.2 exchange rate), and is expected to grow to about 20.2 billion yuan by 2031, with a compound annual growth rate of around 5%.

These numbers point to a clear conclusion: protein research and related services are in a period of rapid growth. Downstream applications—from basic scientific research to new drug development, from synthetic biology to in vitro diagnostics—are continuously expanding, and the demand for high-quality protein products and R&D services keeps rising.

2. The "Four Great Mountains" of Protein Research

 The Four Major Challenges in Protein Research

The demand is skyrocketing, but the supply side hasn’t kept up.

Looking across the entire industry, protein research companies generally face four major technical bottlenecks:

The first mountain: Uncertainty in expression and purification. Different target proteins have significant differences in their physical and chemical properties. In a chosen expression system, there’s huge uncertainty in soluble expression efficiency, the native spatial conformation after purification, and biological activity. Some proteins easily form inclusion bodies or degrade, and from constructing the gene sequence to obtaining a qualified protein product, the trial-and-error cycle can often last for months.

The second mountain: Complexity of protein design. If you want to perform directed evolution on an enzyme, you need to screen potential mutations from an enormous sequence space. Traditional methods rely on random mutagenesis and high-throughput screening, which require large investment, long cycles, and extremely high experience from researchers.

The third mountain: Disconnect between computational and wet experiments. Computational design results often require a lot of wet-lab experiments to verify, and the experimental data can’t efficiently feed back into the next round of design, creating a typical “island-style” R&D model. The gap between computation and experimentation is a key factor limiting research efficiency.

The fourth mountain: High barriers in talent and technology. Protein researchers with interdisciplinary skills are already scarce, and setting up a complete system for design, expression, purification, and validation requires huge investment. This leads many promising research ideas to get stuck at the stage of “wanting to, but can’t do.”

All these bottlenecks together make protein research a field of “high investment, long cycles, and high risk.” But for protein research companies, these pain points are exactly where the value lies—whoever can first connect the entire chain from computational design to experimental validation can claim the high ground in the industry.

3. AI is Reshaping the "Rules of the Game" in Protein Research

In recent years, breakthroughs in AI technology have been systematically changing the landscape.

In April 2026, Shanghai Tianwu Technology officially launched the conversational protein R&D intelligent agent—MatwingsVenus™ (Xiaowu™), a one-stop protein research platform centered around intelligent agents. The platform supports the retrieval of hundreds of billions of real-labeled protein data points and integrates over 200 protein design tools, more than 50 platform-certified experts, and over 30 skill sets fine-tuned by specialists across various fields.

On this platform, users simply input their task goals in natural language, and the system will automatically break down the tasks, carrying out deep research, enzyme mining, directed evolution, de novo design, and automated wet lab collaboration.

The core breakthrough of this model lies in bridging the long-standing "dry-wet loop" problem in the industry—design equates validation, and validation drives iteration. In a typical workflow, after a user completes an AI-driven design, the results can be imported into plasmid ordering and experimental scheduling workflows via the platform’s self-built communication mechanism. Subsequent experimental tasks are then automatically linked, allowing robots to handle sample preparation, protein purification, and functional testing, and finally feeding the experimental results back into the next round of AI design, creating a closed loop where computation drives wet experiments and wet experiments inform computation.

The real-world effectiveness of this approach has been validated in actual projects. For example, in a de novo design project targeting an immunoregulatory receptor, the platform successfully produced dozens of entirely new binder molecules with in vitro cell-blocking activity, completing the full verification process for de novo design.

In May 2026, the platform launched an enterprise version, adding a team intelligent management backend for unified management of budgeting, personnel, risk control, and progress tracking, enabling protein research teams to handle the entire workflow from design to management on a single platform. The mobile app version released the same month further extends protein R&D capabilities to mobile devices, allowing users to initiate protein research tasks anytime, anywhere.

4. Breakthrough Strategies for Protein Research Companies

 A Breakthrough Strategy for Protein Research Companies

From the practice on platforms like MatwingsVenus™ (Xiaowu™), we can clearly see that the value logic of protein research companies is shifting.

In the past, protein research companies were more like "technology service providers," where clients提出需求, and the companies would meet them through experimental techniques. In this model, value creation relied heavily on the skill level and experience of lab personnel, making it difficult to achieve scalable efficiency.

The new generation of platform-based protein research companies, however, are becoming "capability enablers." Clients not only purchase products and services but, more importantly, gain access to a systematic set of R&D capabilities. Platform tools and standardized processes make protein design, expression, and validation replicable and scalable, significantly lowering the R&D barrier for clients and shortening the development cycle.

Take the MatwingsVenus™ (Xiaowu™) platform as an example: its core value is reflected on three levels:

Efficiency: Accelerating protein design through AI, compressing development cycles that would originally take months or even longer.

Capability: Making complex R&D capabilities that only large institutions could afford available to individual developers and small-to-medium teams through a platform approach.

Ecosystem: By integrating design tools, expert resources, and automated experimental capabilities, it builds a sustainable, iterative R&D ecosystem.

This is the unique value of protein research companies in the industry—not just solving a specific technical problem, but reshaping the entire R&D process, making the transition from "good ideas" to "great products" faster and more certain.

Looking ahead, as AI and automated experimental technologies continue to combine, the fundamental logic of the protein research industry is being redefined. From “trial-and-error” to “intelligent design,” from “isolated R&D” to “closed-loop iteration,” this shift will profoundly affect every practitioner.

For protein research companies, whoever first connects the full chain from AI design to experimental validation to industrial implementation will gain the leading edge in the next decade. For researchers, the choice of partners and R&D platforms will directly affect the speed and success rate of turning innovative ideas into reality.

In this era where speed wins, the efficiency revolution in protein research is just getting started.